Founded: 1997

HQ: Pittsburgh, PA

Addressing acute respiratory failure

ALung Technologies began in 1997 as a spin-out of the University of Pittsburgh with a mission to enhance the quality of life, improve the health, and reduce the cost of care for respiratory failure patients and their families.

ALung does this by developing revolutionary respiratory assist products and services, including its flagship solution, the Hemolung RAS.

The Hemolung RAS has been approved for use in European markets since 2013 and is currently conducting a pivotal clinical trial for US markets.

ALung's Hemolung RAS benefits

ALung Technologies icon

Effective and Efficient

Patented "active mixing" technology provides highly efficient CO2 removal at blood flow rates of only 350 - 550 ml per minute.

Alung Technologies icon

Minimally Invasive

Requiring just one 15.5 French dual-lumen venous catheter and minimal anticoagulation.

ALung Technologies icon

Simple to Implement

It's safe and simple to set up and offers advanced monitoring and real-time measurement of CO2 removal.